Skip to main content

Table 3 Risk factors for 3-month mortality of PJP with rheumatic disease

From: High incidence and mortality of Pneumocystis jirovecii infection in anti-MDA5-antibody-positive dermatomyositis: experience from a single center

 

Univariable

Multivariable

Clinical factors

HR (95% CI)

P value

HR (95% CI)

P value

Assessed age

0.981 (0.951–1.012)

0.225

0.975 (0.940–1.010)

0.158

Gender

0.437 (0.207–0.923)

0.798

*

*

MDA5+ DM

2.830 (1.067–7.505)

0.037

3.254 (1.209–8.756)

0.02

AAV

0.674 (0.089, 5.099)

0.702

*

*

SLE

1.062 (0.346, 3.265)

0.916

*

*

CD4+ T cell counts

0.995 (0.989–1.001)

0.083

0.994 (0.989–1.000)

0.04

Lymphocyte counts

0.142 (0.025–0.808)

0.028

*

*

Interstitial lung disease

1.537 (0.540–4.375)

0.421

*

*

Steroid dose

0.291 (0.063, 1.350)

0.115

*

*

Cyclophosphamide

1.807 (0.586, 5.568)

0.303

*

*

Rituximab

0.854 (0.113, 6.450)

0.878

*

*

Time to anti-PJP treatment

1.577 (0.607–4.099)

0.35

*

*

Disease duration

1.003 (0.988–1.018)

0.677

*

*

  1. CI confidence interval, AAV ANCA-associated vasculitis, SLE systemic lupus erythematosus
  2. *Not included in the multivariable model due to the lack of significant association in the univariable analysis